Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > New Press Release - Sirona Biochem Corporate Update

<< Previous

Bullboard Posts

Next >>

Comment by MirrorWorldManon Jul 13, 2023 10:44pm

155 Views

Post# 35540600

RE:RE:RE:New Press Release - Sirona Biochem Corporate Update

So no money and after 11 years of fumbles they finally abandoned the SGLT2 for another one. But it's not Howie fault, blame WannaBang for withholding data and the lost partners for seeing it's another meetoo SGLT 2 in a saturated flozin market & with no endpoint data. Eureka. So they will dump scarce resources into research to develop more molecules to fumble. Wheels of the bus go round and round. All this effort and self reflection to realize they cannot spread themselves too thin and hire consultants..Brilliant.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario